Last day of trading with the warrants of series TO1 2019
Press release: Uppsala, October 13, 2020. Today, October 13, is the last day of trading with the warrants of series TO1 2019. The subscription period for the warrants of series TO1 2019 will continue up until October 15, 2020. Each warrant entitles the owner to subscribe for one point eighty-four (1.84) new shares in Dicot at a price of SEK 1.42 per share after adjustment. In order for the warrants to not expire without value it is required that the owner actively subscribes for new shares at latest October 15, 2020 or sell their warrants at latest October 13, 2020.
Summarized terms for the warrants of series TO1 2019:
Subscription period: October 1 – October 15, 2020.
Size of issue: 7,790,825 warrants of series TO1 2019, which entitles the owners to 14,335,118 shares. If all the warrants are exercised, they will bring in SEK 20,355,861.88 to Dicot.
Subscription price: After the adjustment according to the press release September 29, 2020, the subscription price has been set to SEK 1.42 per share.
Last day for trading warrants of series TO1 2019: October 13, 2020.
Terms in full for the warrants are available at the Company’s website, https://www.dicot.se/investerare-media/teckningsoptioner-20192020/.
How warrants are used:
Trustee registered warrants (Custody account)
Subscription and payment with the use of warrants shall be made in accordance with instructions from each trustee. Please contact your trustee for additional information.
Directly registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.
The warrants will then be replaced by interim shares (IS) awaiting registration at the Swedish Companies Registration Office.
Mangold Fondkommission is the financial adviser, and Advokatfirman Lindahl is the legal adviser, for Dicot regarding the warrants.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5030 1595
E-mail: [email protected]
For additional information, please contact:
Göran Beijer, CEO
Tel: +46 70-663 60 09
E-mail: [email protected]
Dicot AB in brief
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The Company's lead drug candidate, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 1,600 shareholders. For more information see www.dicot.se.
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference
OSLO, Norway, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig, will present and host 1x1 meetings...
Lipum to participate in following upcoming events
BIO-Europe Spring | March 20–22, 2023 | Basel, SwitzerlandLSX World Congress | May 3-4, 2023 | London, UKRedeye Investor Forum | May 11, 2023 | Malmö, SwedenBioStock Life Science Summit Spring | May 30-31, 2023 | DigitalBIO International Convention | June 5-8, 2023 | Boston, MA, USA “Our phase 1 cli...
Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELE...
aXichem expects increased sales of aXivite within dietary supplements in the US and EU over the next twelve months
aXichem AB (publ), which develops and markets natural analogue industrial chemicals, announces that it expects significantly increased sales over the next twelve months of the company's natural analogue product phenylcapsaicin in the area of dietary supplements and nutraceuticals, where the produc...